BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nichols TC, Dillow AM, Franck HW, Merricks EP, Raymer RA, Bellinger DA, Arruda VR, High KA. Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency. ILAR J 2009;50:144-67. [PMID: 19293459 DOI: 10.1093/ilar.50.2.144] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Nichols T, Whitford MH, Arruda VR, Stedman HH, Kay MA, High KA. Translational Data from AAV-Mediated Gene Therapy of Hemophilia B in Dogs. Human Gene Therapy Clinical Development 2015. [DOI: 10.1089/hum.2014.153] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Porada CD, Almeida-Porada G. Treatment of Hemophilia A in Utero and Postnatally using Sheep as a Model for Cell and Gene Delivery. J Genet Syndr Gene Ther 2012;S1:011. [PMID: 23264887 DOI: 10.4172/2157-7412.S1-011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
3 Porada CD, Rodman C, Ignacio G, Atala A, Almeida-Porada G. Hemophilia A: an ideal disease to correct in utero. Front Pharmacol. 2014;5:276. [PMID: 25566073 DOI: 10.3389/fphar.2014.00276] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
4 Limberis MP. Phoenix rising: gene therapy makes a comeback. Acta Biochim Biophys Sin (Shanghai) 2012;44:632-40. [PMID: 22623503 DOI: 10.1093/abbs/gms036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
5 Yen CT, Fan MN, Yang YL, Chou SC, Yu IS, Lin SW. Current animal models of hemophilia: the state of the art. Thromb J 2016;14:22. [PMID: 27766048 DOI: 10.1186/s12959-016-0106-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
6 Siner JI, Iacobelli NP, Sabatino DE, Ivanciu L, Zhou S, Poncz M, Camire RM, Arruda VR. Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype. Blood 2013;121:4396-403. [PMID: 23372167 DOI: 10.1182/blood-2012-10-464164] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 5.6] [Reference Citation Analysis]
7 Nichols TC, Franck HW, Franck CT, De Friess N, Raymer RA, Merricks EP. Sensitivity of whole blood clotting time and activated partial thromboplastin time for factor IX: relevance to gene therapy and determination of post-transfusion elimination time of canine factor IX in hemophilia B dogs. J Thromb Haemost 2012;10:474-6. [PMID: 22482117 DOI: 10.1111/j.1538-7836.2011.04613.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
8 Rapti K, Louis-Jeune V, Kohlbrenner E, Ishikawa K, Ladage D, Zolotukhin S, Hajjar RJ, Weber T. Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol Ther 2012;20:73-83. [PMID: 21915102 DOI: 10.1038/mt.2011.177] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 8.3] [Reference Citation Analysis]
9 Porada CD, Sanada C, Long CR, Wood JA, Desai J, Frederick N, Millsap L, Bormann C, Menges SL, Hanna C, Flores-Foxworth G, Shin T, Westhusin ME, Liu W, Glimp H, Zanjani ED, Lozier JN, Pliska V, Stranzinger G, Joerg H, Kraemer DC, Almeida-Porada G. Clinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A. J Thromb Haemost 2010;8:276-85. [PMID: 19943872 DOI: 10.1111/j.1538-7836.2009.03697.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
10 Liras A. Induced human pluripotent stem cells and advanced therapies. Thrombosis Research 2011;128:8-13. [DOI: 10.1016/j.thromres.2011.01.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
11 Cantore A, Ranzani M, Bartholomae CC, Volpin M, Valle PD, Sanvito F, Sergi LS, Gallina P, Benedicenti F, Bellinger D, Raymer R, Merricks E, Bellintani F, Martin S, Doglioni C, D'Angelo A, VandenDriessche T, Chuah MK, Schmidt M, Nichols T, Montini E, Naldini L. Liver-directed lentiviral gene therapy in a dog model of hemophilia B. Sci Transl Med 2015;7:277ra28. [PMID: 25739762 DOI: 10.1126/scitranslmed.aaa1405] [Cited by in Crossref: 80] [Cited by in F6Publishing: 81] [Article Influence: 13.3] [Reference Citation Analysis]
12 High KA, Aubourg P. rAAV human trial experience. Methods Mol Biol. 2011;807:429-457. [PMID: 22034041 DOI: 10.1007/978-1-61779-370-7_18] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 4.8] [Reference Citation Analysis]
13 Scola MR, Baggesen LM, Nichols TC, Key NS, Gallippi CM. A review of current methods for assessing hemostasis in vivo and introduction to a potential alternative approach. Thromb Res 2012;129 Suppl 2:S57-61. [PMID: 22405050 DOI: 10.1016/j.thromres.2012.02.035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
14 Knudsen T, Kristensen AT, Sørensen BB, Olsen OH, Stennicke HR, Petersen LC. Characterization of canine coagulation factor VII and its complex formation with tissue factor: canine-human cross-species compatibility: Canine-human FVIIa-TF cross-species compatibility. Journal of Thrombosis and Haemostasis 2010;8:1763-72. [DOI: 10.1111/j.1538-7836.2010.03931.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
15 Nichols TC, Bellinger DA, Merricks EP, Raymer RA, Kloos MT, Defriess N, Ragni MV, Griggs TR. Porcine and canine von Willebrand factor and von Willebrand disease: hemostasis, thrombosis, and atherosclerosis studies. Thrombosis 2010;2010:461238. [PMID: 22091368 DOI: 10.1155/2010/461238] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
16 Muto A, Yoshihashi K, Takeda M, Kitazawa T, Soeda T, Igawa T, Sampei Z, Kuramochi T, Sakamoto A, Haraya K, Adachi K, Kawabe Y, Nogami K, Shima M, Hattori K. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood 2014;124:3165-71. [PMID: 25274508 DOI: 10.1182/blood-2014-07-585737] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 6.8] [Reference Citation Analysis]
17 Arruda VR, Weber J, Samelson-Jones BJ. Gene Therapy for Inherited Bleeding Disorders. Semin Thromb Hemost 2021;47:161-73. [PMID: 33636747 DOI: 10.1055/s-0041-1722862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Siner JI, Samelson-Jones BJ, Crudele JM, French RA, Lee BJ, Zhou S, Merricks E, Raymer R, Nichols TC, Camire RM, Arruda VR. Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models. JCI Insight 2016;1:e89371. [PMID: 27734034 DOI: 10.1172/jci.insight.89371] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
19 Finn JD, Ozelo MC, Sabatino DE, Franck HW, Merricks EP, Crudele JM, Zhou S, Kazazian HH, Lillicrap D, Nichols TC, Arruda VR. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood 2010;116:5842-8. [PMID: 20876851 DOI: 10.1182/blood-2010-06-288001] [Cited by in Crossref: 106] [Cited by in F6Publishing: 105] [Article Influence: 8.8] [Reference Citation Analysis]
20 Barnard LR, Leblond G, Nykamp SG, Gaitero L. Spontaneous thoracolumbar hematomyelia secondary to hemophilia B in a cat. JFMS Open Rep 2015;1:2055116915597239. [PMID: 28491378 DOI: 10.1177/2055116915597239] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Knudsen T, Kristensen AT, Nichols TC, Agersø H, Jensen AL, Kjalke M, Ezban M, Tranholm M. Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dog. Haemophilia 2011;17:962-70. [PMID: 21645178 DOI: 10.1111/j.1365-2516.2011.02536.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
22 Monahan PE. The expanding menagerie: animal models of hemophilia A: Hemophilia A animal models. Journal of Thrombosis and Haemostasis 2010;8:2469-71. [DOI: 10.1111/j.1538-7836.2010.04053.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
23 Brooks MB, Stokol T, Catalfamo JL. Comparative Hemostasis: Animal Models and New Hemostasis Tests. Clinics in Laboratory Medicine 2011;31:139-59. [DOI: 10.1016/j.cll.2010.10.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
24 Wolfe JH. Gene therapy in large animal models of human genetic diseases. Introduction. ILAR J. 2009;50:107-111. [PMID: 19293455 DOI: 10.1093/ilar.50.2.107] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
25 Sabatino DE, Freguia CF, Toso R, Santos A, Merricks EP, Kazazian HH Jr, Nichols TC, Camire RM, Arruda VR. Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model. Blood 2009;114:4562-5. [PMID: 19770361 DOI: 10.1182/blood-2009-05-220327] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 2.8] [Reference Citation Analysis]
26 Nowend KL, Starr-Moss AN, Murphy KE. The function of dog models in developing gene therapy strategies for human health. Mamm Genome 2011;22:476-85. [PMID: 21732191 DOI: 10.1007/s00335-011-9348-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
27 Lozier JN, Nichols TC. Animal models of hemophilia and related bleeding disorders. Semin Hematol 2013;50:175-84. [PMID: 23956467 DOI: 10.1053/j.seminhematol.2013.03.023] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
28 Liras A, Segovia C, Gabán AS. Advanced therapies for the treatment of hemophilia: future perspectives. Orphanet J Rare Dis 2012;7:97. [PMID: 23237078 DOI: 10.1186/1750-1172-7-97] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
29 Shetty KA, Merricks EP, Raymer R, Rigsbee N, Nichols TC, Balu-Iyer SV. Soy Phosphatidylinositol-Containing Lipid Nanoparticle Prolongs the Plasma Survival and Hemostatic Efficacy of B-domain-Deleted Recombinant Canine Factor VIII in Hemophilia A Dogs. J Pharm Sci 2016;105:2459-64. [PMID: 27372547 DOI: 10.1016/j.xphs.2016.05.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
30 Sabatino DE, Nichols TC, Merricks E, Bellinger DA, Herzog RW, Monahan PE. Animal models of hemophilia. Prog Mol Biol Transl Sci 2012;105:151-209. [PMID: 22137432 DOI: 10.1016/B978-0-12-394596-9.00006-8] [Cited by in Crossref: 42] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
31 Almeida-Porada G, Atala A, Porada CD. In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application. Mol Ther Methods Clin Dev. 2016;5:16020. [PMID: 27069953 DOI: 10.1038/mtm.2016.20] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
32 Herrera-Carrillo E, Liu YP, Berkhout B. Improving miRNA Delivery by Optimizing miRNA Expression Cassettes in Diverse Virus Vectors. Hum Gene Ther Methods 2017;28:177-90. [PMID: 28712309 DOI: 10.1089/hgtb.2017.036] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
33 Nichols TC, Levy H, Merricks EP, Raymer RA, Lee ML. Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa. PLoS One 2020;15:e0240896. [PMID: 33112889 DOI: 10.1371/journal.pone.0240896] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
34 Porada CD, Sanada C, Kuo CJ, Colletti E, Mandeville W, Hasenau J, Zanjani ED, Moot R, Doering C, Spencer HT, Almeida-Porada G. Phenotypic correction of hemophilia A in sheep by postnatal intraperitoneal transplantation of FVIII-expressing MSC. Exp Hematol 2011;39:1124-1135.e4. [PMID: 21906573 DOI: 10.1016/j.exphem.2011.09.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]
35 Karpf DM, Kjalke M, Thim L, Agersø H, Merricks EP, Defriess N, Nichols TC, Ezban M. Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs. Haemophilia 2011;17:e963-8. [PMID: 21682818 DOI: 10.1111/j.1365-2516.2011.02580.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
36 Scola MR, Nichols TC, Zhu H, Caughey MC, Merricks EP, Raymer RA, Margaritis P, High KA, Gallippi CM. ARFI ultrasound monitoring of hemorrhage and hemostasis in vivo in canine von Willebrand disease and hemophilia. Ultrasound Med Biol 2011;37:2126-32. [PMID: 22033127 DOI: 10.1016/j.ultrasmedbio.2011.09.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
37 Nichols TC, Hough C, Agersø H, Ezban M, Lillicrap D. Canine models of inherited bleeding disorders in the development of coagulation assays, novel protein replacement and gene therapies. J Thromb Haemost 2016;14:894-905. [PMID: 26924758 DOI: 10.1111/jth.13301] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
38 Nichols TC, Raymer RA, Franck HW, Merricks EP, Bellinger DA, DeFriess N, Margaritis P, Arruda VR, Kay MA, High KA. Prevention of spontaneous bleeding in dogs with haemophilia A and haemophilia B. Haemophilia 2010;16 Suppl 3:19-23. [PMID: 20586797 DOI: 10.1111/j.1365-2516.2010.02255.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
39 Liu YP, Berkhout B. miRNA cassettes in viral vectors: problems and solutions. Biochim Biophys Acta 2011;1809:732-45. [PMID: 21679781 DOI: 10.1016/j.bbagrm.2011.05.014] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 5.2] [Reference Citation Analysis]
40 Østergaard H, Bjelke JR, Hansen L, Petersen LC, Pedersen AA, Elm T, Møller F, Hermit MB, Holm PK, Krogh TN, Petersen JM, Ezban M, Sørensen BB, Andersen MD, Agersø H, Ahmadian H, Balling KW, Christiansen ML, Knobe K, Nichols TC, Bjørn SE, Tranholm M. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood 2011;118:2333-41. [PMID: 21700771 DOI: 10.1182/blood-2011-02-336172] [Cited by in Crossref: 99] [Cited by in F6Publishing: 90] [Article Influence: 9.0] [Reference Citation Analysis]
41 Tamai H, Miyake K, Yamaguchi H, Takatori M, Dan K, Inokuchi K, Shimada T. AAV8 vector expressing IL24 efficiently suppresses tumor growth mediated by specific mechanisms in MLL/AF4-positive ALL model mice. Blood 2012;119:64-71. [PMID: 22025528 DOI: 10.1182/blood-2011-05-354050] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
42 Callan MB, Haskins ME, Wang P, Zhou S, High KA, Arruda VR. Successful Phenotype Improvement following Gene Therapy for Severe Hemophilia A in Privately Owned Dogs. PLoS One 2016;11:e0151800. [PMID: 27011017 DOI: 10.1371/journal.pone.0151800] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
43 Nichols TC, Whitford MH, Arruda VR, Stedman HH, Kay MA, High KA. Translational data from adeno-associated virus-mediated gene therapy of hemophilia B in dogs. Hum Gene Ther Clin Dev 2015;26:5-14. [PMID: 25675273 DOI: 10.1089/humc.2014.153] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
44 Mátrai J, Chuah MK, Vandendriessche T. Preclinical and clinical progress in hemophilia gene therapy: . Current Opinion in Hematology 2010;17:387-92. [DOI: 10.1097/moh.0b013e32833cd4bd] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
45 Markusic DM, Herzog RW. Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia. J Genet Syndr Gene Ther 2012;1:1-9. [PMID: 23565343 DOI: 10.4172/2157-7412.S1-009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 14] [Article Influence: 0.1] [Reference Citation Analysis]
46 Finn JD, Nichols TC, Svoronos N, Merricks EP, Bellenger DA, Zhou S, Simioni P, High KA, Arruda VR. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. Blood 2012;120:4521-3. [PMID: 22919027 DOI: 10.1182/blood-2012-06-440123] [Cited by in Crossref: 77] [Cited by in F6Publishing: 73] [Article Influence: 7.7] [Reference Citation Analysis]
47 Zakas PM, Spencer HT, Doering CB. Engineered Hematopoietic Stem Cells as Therapeutics for Hemophilia A. J Genet Syndr Gene Ther 2011;1:2410. [PMID: 25383239 DOI: 10.4172/2157-7412.S1-003] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
48 Zucko D, Boris-Lawrie K. Circular RNAs Are Regulators of Diverse Animal Transcriptomes: One Health Perspective. Front Genet 2020;11:999. [PMID: 33193584 DOI: 10.3389/fgene.2020.00999] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
49 Wang L, Rosenberg JB, De BP, Ferris B, Wang R, Rivella S, Kaminsky SM, Crystal RG. In vivo gene transfer strategies to achieve partial correction of von Willebrand disease. Hum Gene Ther 2012;23:576-88. [PMID: 22482515 DOI: 10.1089/hum.2011.238] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
50 Li H, Malani N, Hamilton SR, Schlachterman A, Bussadori G, Edmonson SE, Shah R, Arruda VR, Mingozzi F, Wright JF. Assessing the potential for AAV vector genotoxicity in a murine model. Blood. 2011;117:3311-3319. [PMID: 21106988 DOI: 10.1182/blood-2010-08-302729] [Cited by in Crossref: 133] [Cited by in F6Publishing: 132] [Article Influence: 11.1] [Reference Citation Analysis]